Ceesay Abraham 4

What Happened

• Ceesay Abraham, CEO of Rapport Therapeutics (RAPP), sold a total of 8,220 shares in open-market transactions on June 29, 2026, generating gross proceeds of about $327,398. The sales consisted of 7,344 shares at a weighted-average price of $39.77 (proceeds $292,062) and 876 shares at a weighted-average price of $40.34 (proceeds $35,336). These are sales (not purchases) and thus are typically viewed as routine dispositions rather than a direct bullish signal.

Key Details

• Transaction dates: June 29, 2026; Form 4 filed July 1, 2026 (filed timely).
• Prices: 7,344 shares at $39.77 (weighted avg; individual prices ranged $39.25–$40.225 per footnote), 876 shares at $40.34 (weighted avg; individual prices ranged $40.26–$40.50 per footnote).
• Total shares sold: 8,220; total reported proceeds: $327,398.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Notable footnotes:
  • Trades were effected under a Rule 10b5-1 trading plan adopted March 27, 2026 (prearranged plan).
  • Weighted-average prices reported; footnotes commit to provide breakdowns on request.
  • Certain shares are held in family irrevocable trusts; the reporting person disclaims beneficial ownership of those trust holdings except to the extent of any pecuniary interest.

Context

• Trades under a 10b5-1 plan are pre-scheduled and commonly used to avoid concerns about insider timing; they do not necessarily indicate the insider’s current view of the company’s prospects.
• These entries are sales (transaction code S). For retail investors, purchases usually carry more direct interpretive weight; routine sales by insiders are common and can be for many personal reasons unrelated to company performance.